**Articles**

**Sex differences in IV thrombolysis treatment for acute ischemic stroke: A systematic review and meta-analysis**

This updated meta-analysis of 24 studies published between 2008 and 2018 found 13% lower odds of IV recombinant tissue plasminogen activator treatment in women. The results show that although the magnitude of the disparity has decreased, it persists, and more action is needed to ensure equitable access to stroke therapy for women and men.

Page 18

**Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS**

Biomarkers are needed for phase II clinical trials of amyotrophic lateral sclerosis (ALS) therapies. In a study comparing several neurofilament assays, serum neurofilament light, but not phosphorylated neurofilament heavy, emerged as a clinically validated biomarker with both prognostic and potential pharmacodynamic utility for ALS.

Page 22

**Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases**

Anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5) was identified recently in some patients with dermatomyositis, but the clinical phenotype has not been described fully. This study found that patients who are anti-MDA5+ have 3 distinct systemic syndromes, each associated with a different prognosis.

Page 23

*Continued*
White matter hyperintensity burden in acute stroke patients differs by ischemic stroke subtype

White matter hyperintensity (WMH) is a radiologic marker with prognostic implications. In an international, multicenter, hospital-based cohort of patients with acute stroke, the extent of WMH burden differed according to the putative etiology, with the highest burden in patients with small vessel disease.

NEW EPISODE

Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease (see the June issue of Neurology® Genetics)

1. Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease
2. What’s Trending: Telephone-based cognitive-behavioral therapy for depression in Parkinson disease: A randomized controlled trial

In the first segment, Dr. Jason Crowell talks with Dr. Daniel Claassen about his Neurology: Genetics paper on genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease. In the second part of the podcast, Dr. Jeffrey Ratliff focuses his discussion with Dr. Roseanne Dobkin on telephone-based CBT for depression in patients with Parkinson disease.

Disclosures can be found at Neurology.org.

No CME this week: Interviews based on articles from Neurology® Clinical Practice, Neurology: Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from the CME program.
Spotlight on the July 7 issue
José G. Merino
Neurology 2020;95:1-2
DOI 10.1212/WNL.0000000000009852

This information is current as of July 6, 2020

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://n.neurology.org/content/95/1/1.full">http://n.neurology.org/content/95/1/1.full</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a></td>
</tr>
</tbody>
</table>